Autolus(US:AUTL)2020-09-11 18:21AUTO1 - Adult Acute Lymphoblastic Leukemia (ALL) - AUTO1 is designed for adult ALL patients, aiming for high activity, long persistence, and good tolerability [12, 13] - In a study with all patients, AUTO1 achieved a complete remission (CR) rate of 84%, and with a closed process, the CR rate was 92% [20] - At 6 months, the event-free survival (EFS) for all patients was 62%, and for those treated with the closed manufacturing process, it was 76% [20] - The company is on track for full data from the pivotal study AUTO1-AL1 by the end of 2021 [31] AUTO3 - Diffuse Large B Cell Lymphoma (DLBCL) - AUTO3, combined with pembrolizumab, demonstrated an overall response rate (ORR) of 65% and a complete response rate (CRR) of 48% across all dose levels [39] - At dose levels ≥ 150 x 10^6 cells, the ORR was 69% and the CRR was 56% [39] - At dose levels ≥ 150 x 10^6 with Day -1 pembro, the ORR was 75% and the CRR was 63% [39] - Notably, there were no Grade 3 or higher cytokine release syndrome (CRS) events observed at ≥ 150 x10^6 cell dose [35] Pipeline and Future Development - The company has a broad pipeline of next-generation programs designed to address limitations of current T cell therapies [8, 69] - Autolus plans to start Phase 1 trials for AUTO1NG, AUTO8 in H2 2020, and AUTO5, AUTO6NG, AUTO7 in 2021 [70, 95] - The company had $212 million cash on hand as of June 30, 2020 [97]